Q4 result impact: Dalmia Bharat Sugar shares up 9% as PAT more than doubles, GSK Pharma and AB Capital shares rise 5%

Q4 result impact: Dalmia Bharat Sugar shares jump 9% as net profit zooms 126%, GSK Pharma, AB Capital shares rise 5%

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

Choose Stock Exchange: BSE LIVE NSE LIVE

26 Aug, 2025 12:21

Volume

Todays L/H

More

×

The shares of Dalmia Bharat Sugar surged nearly 9 percent on May 14 after the company reported a 126 percent rise in net profit at Rs 206 crore for the fourth quarter of the financial year 2025. GSK Pharma and Aditya Birla Capital shares too gained by around 5 percent each.

The companies had released their respective Q4FY25 results post-market hours on May 13.

Dalmia Bharat Sugar

Sugar and industrial alcohol supplier Dalmia Bharat Sugar on May 13 reported a net profit of Rs 206 crore for Q4FY25, marking a 126 percent rise from the Rs 91 crore net profit reported a year ago. The revenue from operations meanwhile surged around 36 percent on-year to Rs 1,018 crore. The firm also reported its highest ever EBITDA at Rs 215 crore.

"Q4FY25 was a landmark quarter for the company, marked by strong financial performance, including the highest-ever EBITDA and PAT. This was driven by record-high average sales realizations and strong revenue from operations," the firm said.

Along with the Q4 results, the company announced a final dividend of Rs 1.50 per equity share for the financial year 2025. The record date to determine the eligibility of the shareholders set to receive the payment is yet to be announced.

The shares of the company have seen a string surge recently, rising over 18 percent in the past five days. The stock has gained over 21 percent in 2025 so far.

GSK Pharma

Medicine and vaccine maker GSK Pharma reported a net profit of Rs 262.87 crore for the fourth quarter of the financial year 2025. This marks a rise of over 35 percent from the Rs 194.48 crore net profit reported in the corresponding quarter of the previous financial year. Revenue from operations meanwhile rose to Rs 974.37 crore.

"We remain committed to delivering sustained above-market growth and strong shareholder returns. In FY2025-26, we will continue to focus on our innovative portfolio through the launch of our oncology assets," said GSK Pharma's Managing Director Bhushan Akshikar.

Along with the fourth quarter results, the company announced a final dividend of Rs 42 per equity share for the financial year 2025. The dividend will be paid to the eligible shareholders on or after June 30.

Motilal Oswal maintained a 'Neutral' rating on the stock, with a target price to Rs 3,040 apiece. This implies an upside potential of over 9 percent from the stock’s previous closing price of Rs 2,789 apiece. The brokerage said the pharma company’s sales were in-line with its estimates. "However, it delivered a beat on EBITDA/PAT due to a superior product mix and controlled costs," it added.

The shares of the company surged nearly 5 percent to trade at Rs 2,926 apiece in the morning. The stock has risen nearly 30 percent in 2025 so far.

Aditya Birla Capital

Financial services company Aditya Birla Capital reported a net profit of Rs 864.60 crore for the fourth quarter of the financial year 2025. This marks a fall of nearly 31 percent from the Rs 1,245.41 crore net profit reported in the corresponding quarter of the previous financial year. However, the previous year's fourth quarter net profit included a one-time gain, barring which the figure would have stood at Rs 812 crore.

Revenue from operations meanwhile rose to Rs 12,238.92 crore. "ABCAP continued to exhibit an improvement in operational metrics in 4QFY25. Loan growth remained healthy across both the HFC and NBFC segments, accompanied by a further improvement in asset quality. While NIMs in the NBFC business witnessed some contraction during the quarter, management has guided for NIM improvement in the subsequent quarters, supported by a favorable shift in its product mix," Motilal Oswal said.

The brokerage reiterated its 'Buy' rating on the stock, with a target price of Rs 250 apiece. This implies an upside potential of over 22 percent from the stock’s previous closing price of Rs 204.89 apiece.

The shares of the company rose nearly 6 percent to trade at Rs 217 apiece. The stock has so far risen nearly 21 percent in 2025 so far. It has jumped nearly 9 percent in the past five days.

Disclaimer: The views and investment tips expressed by experts on Moneycontrol are their own and not those of the website or its management. Moneycontrol advises users to check with certified experts before taking any investment decisions.